Chronic graft versus host disease in skin – Diagnostics – Overview of Information and Clinical Research

Chronic graft versus host disease in the skin is a serious complication that can occur after a bone marrow or stem cell transplant, when the donor’s immune cells attack the recipient’s skin and other organs. Understanding the diagnostic process is essential for patients who have undergone transplantation, as early detection and treatment can help manage symptoms and improve quality of life.

Introduction: Who Should Undergo Diagnostics

Anyone who has received an allogeneic hematopoietic stem cell transplant—which means receiving stem cells from another person—should be aware of the possibility of developing chronic graft versus host disease, or chronic GVHD, in their skin. This condition affects approximately 40 to 60 percent of people who undergo this type of transplant, making it one of the most common long-term complications following the procedure.^[1]^[2]

The skin is not only the most frequently affected organ in chronic GVHD, but it is also usually the first place where signs of the disease appear. In fact, skin involvement occurs in roughly 70 percent of patients who develop chronic GVHD.^[3] Because skin changes are often the presenting sign of this condition, patients should seek diagnostic evaluation whenever they notice unusual skin symptoms after their transplant.

Chronic GVHD typically develops after 100 days following the transplant, though it can appear at any time. Most cases start within the first two years after the transplant procedure.^[4] Patients should be particularly vigilant during this period and report any changes to their healthcare team promptly. Some people develop chronic GVHD even without having experienced acute GVHD earlier—this is known as “de novo” chronic GVHD and accounts for approximately 25 to 35 percent of cases.^[13]

It is advisable to seek diagnostic evaluation if you notice any of the following skin changes: changes in skin texture such as thickening or tightening, unusual spots or discoloration, persistent itching, skin dryness and cracking, rashes that resemble sunburn, changes to your nails such as ridging or splitting, or hair loss on your scalp or body.^[2]^[3] These symptoms can develop gradually, and some people may not immediately recognize them as potentially serious. However, early diagnosis allows treatment to begin sooner, which can help prevent the condition from worsening and causing permanent damage.

⚠️ Important

Do not ignore skin changes after your transplant, even if they seem minor. Chronic GVHD can be easier to manage when caught early. Contact your transplant doctor or specialist nurse as soon as you notice any unusual skin symptoms, changes in your range of motion, or problems with your nails or hair.

Diagnostic Methods

Diagnosing chronic GVHD in the skin requires careful clinical evaluation because the condition can look very similar to other well-known inflammatory and autoimmune disorders. This overlap in appearance makes it challenging for doctors to establish a definite diagnosis based on visual examination alone.^[1] The diagnostic process typically involves several different approaches working together to confirm the presence of chronic GVHD and rule out other possible conditions.

Physical Examination and Medical History

The first step in diagnosing chronic GVHD of the skin is a thorough physical examination by your healthcare professional. During this examination, your doctor will carefully inspect your skin, looking at the type, location, and extent of any rashes, discoloration, or texture changes. They will also review your complete medical history, paying particular attention to when you had your transplant, whether you experienced acute GVHD previously, and when your current symptoms first appeared.^[6]

The doctor will assess various aspects of your skin condition, including whether there is thickening or tightening of the skin, changes in pigmentation such as lighter or darker areas, the presence of rashes or spots, and whether your skin shows signs similar to conditions like lichen planus (an inflammatory skin condition), morphoea (a type of localized scleroderma), or lichen sclerosus (a chronic inflammatory skin condition).^[2] These patterns help distinguish chronic GVHD from other skin diseases.

Your doctor will also examine your nails for changes such as longitudinal ridging or splitting, separation of the nail from the nail bed (called onycholysis), wing-like growths (called pterygium), or complete nail loss. Hair examination includes checking for scarring or non-scarring hair loss on the scalp, scaling, and loss of body hair.^[2] These features, when combined with skin findings, strengthen the diagnosis of chronic GVHD.

Skin Biopsy

A skin biopsy is often performed to help confirm the diagnosis of chronic GVHD. During this procedure, a small sample of skin tissue is removed and examined under a microscope by a specialist called a pathologist. The biopsy can reveal specific changes in the skin cells and tissue structure that suggest GVHD, though the findings can sometimes overlap with those seen in other conditions.^[1]

The biopsy procedure itself is relatively straightforward. The doctor will clean the area and numb it with a local anesthetic so you do not feel pain during the procedure. Then, a small piece of skin is removed using a special instrument. The sample is sent to a laboratory where it undergoes processing and staining so that the pathologist can examine the cellular details and tissue architecture. The results typically take several days to return.

However, it is important to understand that while a biopsy can support the diagnosis, the frequent overlapping of both clinical appearance and microscopic findings of chronic GVHD with other conditions means that a biopsy alone may not provide a definitive answer.^[1] Doctors must interpret the biopsy results in combination with your medical history, symptoms, and physical examination findings to reach a final diagnosis.

Distinguishing Chronic GVHD from Other Conditions

One of the major challenges in diagnosing chronic GVHD of the skin is that it can mimic many other inflammatory and autoimmune skin disorders. The condition may look like lichen planus, morphoea, lichen sclerosus, or even show features resembling poikiloderma (a condition causing skin changes including pigmentation, thinning, and tiny dilated blood vessels).^[1]^[2]

Because chronic GVHD symptoms can also be confused with other health conditions, your healthcare team may need to rule out various alternative diagnoses. This process involves considering your complete medical picture, including the timing of symptom onset relative to your transplant, whether multiple organs are affected beyond just the skin, and how your symptoms respond to initial treatments. Other symptoms affecting your eyes (such as dryness and grittiness), mouth (such as lichen planus-like features or dryness), or joints (such as stiffness or contractures) can provide additional clues that point toward chronic GVHD rather than another condition.^[2]^[6]

Grading the Severity

Once chronic GVHD is diagnosed, your doctor will grade its severity. This grading helps determine the most appropriate treatment plan for your situation. The grading system looks at both the number of organs involved and how severe the involvement is in each organ. Based on this assessment, chronic GVHD is classified as mild, moderate, or severe.^[8]

For skin involvement specifically, doctors assess factors such as the percentage of body surface area affected, whether there is just superficial involvement or deeper sclerotic (hardening) changes, and how the skin changes impact your function. For example, skin tightening that limits your range of motion or prevents you from fully opening your mouth represents more severe disease than a rash covering a small area without functional impact.

Diagnostics for Clinical Trial Qualification

Patients with chronic GVHD who are considering participation in clinical trials for new treatments will undergo additional diagnostic evaluations beyond those used for routine diagnosis. Clinical trials have specific criteria that patients must meet to be eligible, and these criteria help ensure that the trial results are meaningful and that participants are appropriate candidates for the experimental treatment being studied.

For clinical trial enrollment, the diagnosis of chronic GVHD must typically be confirmed according to standardized criteria. These criteria have been developed by expert consensus groups to ensure that different medical centers and research teams are identifying chronic GVHD in the same way. The confirmation process usually requires documentation of characteristic clinical features that are distinctive for chronic GVHD—these are signs and symptoms that would not be explained by other conditions.^[1]

Many clinical trials require that patients have failed or shown inadequate response to at least one or two prior lines of treatment before they can enroll. For example, a trial might require that you have chronic GVHD that has not responded adequately to treatment with corticosteroids (also called steroids, which are medications that dampen down the immune system), which are typically the first-line treatment. This requirement ensures that the trial is testing treatments for patients who need alternative options beyond standard therapy.^[6]

Before enrolling in a clinical trial, you will likely undergo a comprehensive assessment of your chronic GVHD that documents the specific organs affected, the severity of involvement in each organ, and your overall functional status. This baseline assessment serves as a starting point for measuring whether the experimental treatment helps improve your condition. For skin GVHD, this assessment will include detailed documentation of the type and extent of skin changes, photographs of affected areas, measurements of skin thickening or tightening, and assessment of how the skin disease affects your ability to perform daily activities.

Clinical trials may also require specific laboratory tests to ensure that your overall health is sufficient to safely receive the experimental treatment. These might include blood tests to check your liver and kidney function, blood cell counts, and other measures. Some trials may have age restrictions or requirements about how long it has been since your transplant. Your research team will review all these criteria with you to determine whether you are eligible to participate.

⚠️ Important

Clinical trials offer access to new treatments that may help when standard therapies have not been effective. However, enrollment requires meeting specific criteria, and the experimental nature of the treatment means that benefits are not guaranteed. Talk with your transplant team about whether a clinical trial might be appropriate for your situation, and make sure you understand both the potential benefits and risks before deciding to participate.

Prognosis and Survival Rate

Prognosis

The outlook for patients with chronic graft versus host disease in the skin varies considerably depending on several factors. The severity of skin involvement, the number of other organs affected, and how well the condition responds to treatment all play important roles in determining the course of the disease.^[1] Many people with chronic GVHD see gradual improvement over time, with the average duration of active disease lasting between one and three years, though some people experience symptoms for longer periods.^[12]

Chronic GVHD can have a significant negative impact on quality of life, particularly when it affects multiple body systems. The most commonly reported symptoms include itchy skin, dry mouth, diarrhea, dry eyes, reduced energy levels, and psychological stress.^[2] Skin involvement specifically can lead to problems with sleep due to itching, and when genital areas are affected, it can result in sexual dysfunction.^[2] However, with appropriate treatment and supportive care, many of these symptoms can be managed effectively.

Treatment typically requires immunosuppressive medications for extended periods. About two-thirds of people will show improvement after six months of treatment with prednisone, the primary medication used for chronic GVHD.^[3] When initial treatments do not work adequately, there are more than 20 second-line treatment options that physicians can try.^[3] The goal of treatment is to control symptoms, prevent organ damage, improve physical function, and enhance quality of life.

Patients with skin chronic GVHD face an increased risk of developing skin cancers, so regular monitoring and skin examinations are important parts of long-term follow-up care.^[3] Additionally, secondary malignancies are more common in people with chronic GVHD, particularly in commonly involved tissues such as the mouth and skin, suggesting that chronic inflammation, prolonged exposure to immunosuppressive medications, or immune system problems may facilitate the development of new cancers.^[13]

Survival rate

Chronic graft versus host disease is associated with higher treatment-related mortality compared to patients who do not develop this complication. The condition accounts for 15 percent of deaths following hematopoietic stem cell transplantation and remains the major cause of late death in transplant recipients.^[1]^[13] Despite this association with increased mortality, chronic GVHD is also linked with lower relapse rates of the original disease that required the transplant, because the donor immune cells that cause GVHD also help fight cancer cells.

The functional consequences of chronic GVHD organ involvement, including skin, are major determinants of the health and quality of life of survivors.^[13] While approximately half of affected people have three or more involved organs and may require immunosuppressive medications for a median of one to three years, many patients do achieve resolution or significant improvement of their symptoms over time with appropriate management.^[13]

#1 Clinical Trials Search in Europe